JP2012505234A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505234A5 JP2012505234A5 JP2011531165A JP2011531165A JP2012505234A5 JP 2012505234 A5 JP2012505234 A5 JP 2012505234A5 JP 2011531165 A JP2011531165 A JP 2011531165A JP 2011531165 A JP2011531165 A JP 2011531165A JP 2012505234 A5 JP2012505234 A5 JP 2012505234A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- membered
- cycloalkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- -1 bicyclo [4.2.0] octatrienyl Chemical group 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 150000002431 hydrogen Chemical class 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 3
- 125000002971 oxazolyl group Chemical group 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000008601 Polycythemia Diseases 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10362008P | 2008-10-08 | 2008-10-08 | |
| US61/103,620 | 2008-10-08 | ||
| PCT/US2009/059945 WO2010042684A1 (en) | 2008-10-08 | 2009-10-08 | Pyrrolotriazine kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012505234A JP2012505234A (ja) | 2012-03-01 |
| JP2012505234A5 true JP2012505234A5 (enExample) | 2012-11-08 |
| JP5592890B2 JP5592890B2 (ja) | 2014-09-17 |
Family
ID=41664941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011531165A Expired - Fee Related JP5592890B2 (ja) | 2008-10-08 | 2009-10-08 | ピロロトリアジンキナーゼ阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8445676B2 (enExample) |
| EP (1) | EP2344504B1 (enExample) |
| JP (1) | JP5592890B2 (enExample) |
| CN (1) | CN102245610B (enExample) |
| WO (1) | WO2010042684A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2262806A1 (en) * | 2008-03-06 | 2010-12-22 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| CN102675323B (zh) * | 2012-06-01 | 2014-04-09 | 南京药石药物研发有限公司 | 吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途 |
| US9050345B2 (en) * | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| CN104016983B (zh) * | 2013-10-08 | 2018-11-02 | 上海创诺制药有限公司 | 吡咯并三嗪类衍生物及其制法和用途 |
| WO2015051500A1 (zh) * | 2013-10-08 | 2015-04-16 | 上海创诺制药有限公司 | 吡咯并三嗪类衍生物及其制法和用途 |
| WO2015090496A1 (en) * | 2013-12-17 | 2015-06-25 | Merck Patent Gmbh | N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase |
| CN104974163B (zh) * | 2014-04-14 | 2017-11-07 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| US10550125B2 (en) * | 2015-10-20 | 2020-02-04 | Bristol-Myers Squibb Company | Prodrugs of imidazotriazine compounds as CK2 inhibitors |
| HUE054912T2 (hu) * | 2016-07-14 | 2021-10-28 | Lilly Co Eli | Pirazolil-amino-benzimidazol-származékok mint JAK inhibitorok |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| ES3035284T3 (en) | 2020-07-02 | 2025-09-01 | Incyte Corp | Tricyclic urea compounds as jak2 v617f inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| EP4298099A1 (en) | 2021-02-25 | 2024-01-03 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| JP2025509672A (ja) | 2022-03-17 | 2025-04-11 | インサイト・コーポレイション | Ｊａｋ２ ｖ６１７ｆ阻害剤としての三環式尿素化合物 |
| CA3246424A1 (en) | 2022-04-08 | 2023-10-12 | Shy Therapeutics, Llc | Compounds interacting with proteins of the RAS superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2373990C (en) * | 1999-05-21 | 2007-05-08 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| CN1771234A (zh) * | 2003-02-05 | 2006-05-10 | 布里斯托尔-迈尔斯斯奎布公司 | 吡咯并三嗪激酶抑制剂的制备方法 |
| MY145634A (en) * | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| CN1993130B (zh) * | 2004-06-28 | 2010-06-23 | 布里斯托尔-迈尔斯斯奎布公司 | 用于制备稠合杂环激酶抑制剂的方法和中间体 |
| WO2006044687A2 (en) * | 2004-10-15 | 2006-04-27 | Takeda San Diego, Inc. | Kinase inhibitors |
| US7442700B2 (en) * | 2005-07-01 | 2008-10-28 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| US7514435B2 (en) * | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| MX2008007103A (es) * | 2005-12-02 | 2008-09-12 | Bayer Healthcare Llc | Derivados 4-amino-pirrolotriazina sustituidos, útiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis. |
| EP2041138B1 (en) * | 2006-07-07 | 2014-06-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7531539B2 (en) * | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| WO2008057994A2 (en) * | 2006-11-03 | 2008-05-15 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| EP2134716A1 (en) * | 2007-04-18 | 2009-12-23 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| JP5678661B2 (ja) * | 2007-09-25 | 2015-03-04 | バイエル ヘルスケア エルエルシー | オーロラキナーゼの阻害による癌の治療に有用なピロロトリアジン誘導体 |
| EP2262806A1 (en) | 2008-03-06 | 2010-12-22 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
-
2009
- 2009-10-08 EP EP09793354.3A patent/EP2344504B1/en not_active Not-in-force
- 2009-10-08 JP JP2011531165A patent/JP5592890B2/ja not_active Expired - Fee Related
- 2009-10-08 CN CN200980149134.7A patent/CN102245610B/zh not_active Expired - Fee Related
- 2009-10-08 WO PCT/US2009/059945 patent/WO2010042684A1/en not_active Ceased
- 2009-10-08 US US13/123,305 patent/US8445676B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012505234A5 (enExample) | ||
| AU2014219283C1 (en) | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | |
| ES2285151T3 (es) | Derivados de 1-amido-4-fenil-4-benciloximetil-piperidina y compuestos relacionados como antagonistas de neurocinina-1 (nk-1) para el tratamiento de vomitos, depresion ansiedad y tos. | |
| JP2014508811A5 (enExample) | ||
| JP2008535903A5 (enExample) | ||
| JP2006508935A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2006524222A5 (enExample) | ||
| WO2010042684A4 (en) | Pyrrolotriazine kinase inhibitors | |
| JP2017509689A5 (enExample) | ||
| JP2009535307A5 (enExample) | ||
| WO2009112678A3 (fr) | Derives de carboxam i d es azabicycliques, leur preparation et leur application en therapeutique. | |
| JP2011513305A5 (enExample) | ||
| JP2011510080A5 (enExample) | ||
| JP2009523760A5 (enExample) | ||
| JP2010527985A5 (enExample) | ||
| JP2017532360A5 (enExample) | ||
| JP2009507896A5 (enExample) | ||
| JP2016501185A5 (enExample) | ||
| JP2013540712A5 (enExample) | ||
| JP2014528464A5 (enExample) | ||
| NZ596820A (en) | Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid | |
| EP3452465B1 (en) | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | |
| JP2013544854A5 (enExample) | ||
| JP2015502371A5 (enExample) |